Novo Nordisk A/S vs Visa Inc.: Strategic Comparison

This in-depth comparison examines Novo Nordisk A/S and Visa Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novo Nordisk A/S on its own, evaluating Visa Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novo Nordisk A/S and Visa Inc. is widest.

On the headline numbers, Novo Nordisk A/S reports annual revenue of $42.7B against $40.0B for Visa Inc., while their respective market capitalizations stand at $550.0B and $759.3B. Novo Nordisk A/S is headquartered in Denmark and Visa Inc. operates from United States, and those different home markets shape how each company competes.

Novo Nordisk A/S: A single molecule generated 215.2 billion Danish Krone in FY2024 sales. Semaglutide — marketed as Ozempic for diabetes and Wegovy for obesity — is the most commercially successful pharmaceutical product of the current decade and possibly the most consequential medicine introduced since statins. Novo Nordisk generated 290.42 billion DKK (approximately $42.7 billion) in total FY2024 revenue, and 74% of that revenue came from one chemical compound first synthesized by the company's researchers. That concentration is simultaneously the source of extraordinary financial performance and the central strategic risk of the entire enterprise. Novo Nordisk's origins in 1923 and 1925 as two separate Danish insulin laboratories trace back to August Krogh, a Danish Nobel laureate who learned of insulin's discovery in Canada in 1922 and obtained a license to manufacture it in Scandinavia. For eight decades, the company operated as a high-quality but relatively constrained insulin manufacturer competing in a global market where Eli Lilly, Sanofi, and others were similarly positioned. The incretin class of drugs — GLP-1 receptor agonists that stimulate insulin secretion while suppressing appetite — changed everything. Semaglutide, the optimized GLP-1 agonist that Novo Nordisk developed over fifteen years of research, proved effective not just for blood sugar control but for substantial, sustained weight loss. The company operates from Bagsværd, Denmark, a suburb of Copenhagen where the research and manufacturing infrastructure that produced semaglutide was built over decades. The 77,900 employees across global manufacturing facilities cannot produce Wegovy and Ozempic fast enough to meet demand — a problem that is simultaneously evidence of unprecedented commercial success and a constraint on revenue growth. Novo Holdings, the controlling shareholder, acquired Catalent in 2024 for $16.5 billion specifically to secure additional manufacturing capacity. CEO Lars Fruergaard Jørgensen has been managing a company that grew from $24.8 billion in FY2022 revenue to $42.7 billion in FY2024 — 72% growth in two years — while simultaneously trying to build the manufacturing infrastructure to support a demand trajectory that no pharmaceutical company in history had previously experienced.

Visa Inc.: Every dollar that flows through Visa's network earns the company a fee — but Visa never touches that dollar. The $40 billion in fiscal 2025 revenue comes from a business that holds no deposits, extends no credit, and absorbs no default risk. That architecture, sustained since 1958, makes Visa one of the most capital-efficient businesses ever built. The network spans more than 130 million merchant locations across 200-plus countries. When a cardholder in Manila pays at a terminal in Berlin, Visa's systems authorize, route, and settle that transaction in under two seconds, taking a fraction of a percent along the way. Scale is the engine — more volume means more fee income on essentially the same fixed infrastructure. Revenue grew from $29.3 billion in fiscal 2022 to $40 billion in fiscal 2025, a trajectory driven by cross-border payments recovering after the pandemic, digital commerce growth, and the ongoing global shift away from cash. Net income hit $20.1 billion in 2025, implying margins that most industrial companies would consider impossible. The DOJ debit antitrust lawsuit filed in September 2024 represents the most credible legal threat the company has faced in years. The complaint targets the mechanisms Visa uses to steer debit volume to its own network — the same mechanisms that protect a disproportionate share of its domestic volume from competition. The outcome is uncertain, and the financial exposure is real.

Novo Nordisk A/S and Visa Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novo Nordisk A/S and Visa Inc..

Novo Nordisk A/S business model: For the first 80 years of its existence, the organization operated primarily as a low-margin, high-volume manufacturer of animal-derived and later recombinant human insulins, competing in a crowded market where pricing was heavily regulated by European national health systems and US government procurement contracts. The pricing power inherent in the innovative pharma model allows Novo Nordisk to charge premium list prices in the US market, which accounts for approximately 65% of total global sales. However, this pricing power is heavily distorted by the US pharmacy benefit manager (PBM) system. Novo Nordisk's Insulin glargine (Levemir) and Insulin aspart (NovoLog) are locked in a price war with Sanofi's Lantus and Eli Lilly's Humalog, a battle that has been exacerbated by the introduction of interchangeable biosimilars and the aggressive pricing tactics of the big three PBMs in the US. This strategy of identifying unmet medical needs in complex, chronic diseases and developing targeted therapies to address them is a core component of Novo Nordisk's competitive strategy, allowing the company to command premium pricing and achieve high margins despite the intense competitive pressure in the broader metabolic disease market. While legacy insulin sales declined by 4% due to biosimilar competition and VBP pricing pressure in China, the combined sales of Ozempic (146.9 billion DKK), Wegovy (68.2 billion DKK), and Rybelsus (2.8 billion DKK) demonstrated that the next generation of incretin therapies is achieving commercial scale faster than anticipated. The US market remains the most profitable region, contributing approximately 65% of total revenue but an even higher percentage of operating profit due to the significantly higher pricing power for innovative biologics in the United States compared to Europe and Asia. Concurrently, the company is navigating intense structural pricing pressure in the US, the world's most profitable pharmaceutical market. While the FDA has recently cracked down on these practices, the existence of a parallel, low-cost supply chain has permanently altered patient expectations regarding the pricing of GLP-1 therapies, making it increasingly difficult for Novo Nordisk to maintain its premium list prices without facing intense public and political backlash. The company's deep integration with academic medical centers through its clinical trial network creates a feedback loop of real-world data that accelerates regulatory approvals and label expansions, further entrenching its dominance in the therapeutic area. The company must also navigate the complex and evolving pricing and reimbursement landscape, particularly in the US where the implementation of the Inflation Reduction Act is expected to put significant downward pressure on drug prices.

Visa Inc. business model: Visa's economics are counterintuitive until you grasp one fact: the company sits at the most profitable point in the payment chain precisely because it refuses to do the expensive parts. It doesn't lend. It doesn't hold deposits. It doesn't chase delinquent borrowers or write off bad debt. Those capital-intensive, loss-prone activities belong to the issuing banks — JPMorgan Chase, Citi, HSBC, and thousands of others — who put the Visa logo on their cards and bear the credit risk. Visa operates the plumbing between those banks and the merchants who accept their cards. Every time someone taps, swipes, or types in a card number, Visa's network performs authorization (is this card valid? Does the account have funds?), clearing (what does each party owe?), and settlement (move the money). That three-step process happens in roughly 1.8 seconds across 200+ countries, and Visa charges for each step. The revenue breaks into four streams, and the mix matters: Service revenue (~35% of net revenue) is essentially a tax on spending volume. Visa charges issuing banks a percentage of the total payment volume processed on Visa credentials in the prior quarter. More spending flows through Visa cards, more service revenue arrives — regardless of whether those transactions are large or small, domestic or international. Data processing revenue (~35%) is a per-transaction fee for the authorization, clearing, and settlement work. This scales with transaction count rather than transaction size, which means a $4 coffee generates roughly the same data processing fee as a $4 grocery run. In FY2025, Visa processed approximately 257.5 billion transactions. International transaction revenue (~22%) is the premium layer. When a payment crosses a border or involves currency conversion, Visa charges significantly more — roughly 3x the revenue per dollar of volume compared to domestic transactions. This is why cross-border travel recovery post-pandemic was such a tailwind, and why international e-commerce growth matters disproportionately to the income statement. Value-added services revenue (~27%, with overlap in reporting) comes from everything Visa sells beyond basic transaction routing: fraud prevention tools (Visa Advanced Authorization scores 100% of VisaNet transactions in real time), tokenization services, consulting, data analytics, loyalty infrastructure, Visa Direct real-time push payments, and open banking capabilities through Tink. This segment hit $10.9 billion in FY2025 and is growing faster than the core network fees. The margin structure is what makes Wall Street salivate. Operating margins consistently exceed 65%. Net margins sit above 50% — Visa earned $20.1 billion in net income on $40 billion in revenue in FY2025. The reason is structural: once the network infrastructure exists, the marginal cost of processing an additional transaction is nearly zero. Visa doesn't need more branches, more loan officers, or more capital reserves as volume grows. It needs servers, engineers, and fraud models — all of which scale beautifully. The flywheel is textbook but genuinely powerful: more cardholders make Visa attractive to merchants (why refuse a card that 4.4 billion credentials carry?), more merchant acceptance makes Visa useful to cardholders (why carry a card that isn't accepted?), and both sides generate more transactions that fund better security, faster processing, and new capabilities that make the network even harder to leave. The secular shift from cash to digital payments provides structural volume growth even in mature markets, while emerging markets in Africa, Southeast Asia, India, and Latin America offer decades of additional runway where cash still dominates daily commerce.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novo Nordisk A/S stack up against those of Visa Inc..

Novo Nordisk A/S competitive advantage: The execution of this strategy requires flawless commercial execution and unprecedented manufacturing scale, capabilities that were severely tested in 2023 when the FDA issued warnings to compounding pharmacies that were illegally producing unapproved versions of semaglutide to bypass the official supply shortages. The successful completion of these trials has established semaglutide as a foundational therapy for cardiorenal protection, a competitive advantage that is extremely difficult for new entrants to replicate without conducting their own multi-year, multi-billion dollar outcomes trials. This specific molecular architecture is protected by a dense thicket of composition-of-matter, formulation, and method-of-use patents that do not expire until the mid-2030s, creating a legal barrier to entry that is virtually impossible to close quickly. This clinical data package, encompassing over 100,000 patient-years of exposure across the STEP, SUSTAIN, PIONEER, and SELECT trial programs, represents a competitive advantage that is rooted in deep scientific expertise, massive capital barriers, and regulatory exclusivity. The manufacturing moat is equally formidable. Novo Nordisk operates the largest peptide fermentation facilities in the world, located in Kalundborg, Denmark, which are specifically designed to handle the complex biological processes required to produce semaglutide at commercial scale. The sheer cost and regulatory complexity of building and operating these facilities deter all but the most well-capitalized competitors from attempting to enter the GLP-1 space, giving Novo Nordisk a significant cost and scale advantage that will be difficult to replicate. This regulatory expertise, combined with its manufacturing scale and clinical data dominance, creates a comprehensive competitive advantage that positions Novo Nordisk as the undisputed leader in the rapidly evolving field of incretin therapies. The commercial infrastructure required to support this advantage is equally specialized. If these trials are successful, Novo Nordisk could potentially launch semaglutide for MASH by 2027, establishing another first-mover advantage in a completely new therapeutic area and creating a multi-billion dollar revenue stream that would significantly diversify the company's portfolio. Novo Nordisk has established a dedicated AI and data science hub in Copenhagen, which is focused on developing machine learning algorithms to analyze large-scale biological datasets, identify novel peptide targets, and optimize the design of clinical trials.

Visa Inc. competitive advantage: Here's a thought experiment: you're a billionaire with unlimited capital and you want to build a Visa competitor from scratch. Where do you start? You'd need to convince thousands of banks across 200+ countries to issue cards on your network instead of (or alongside) Visa. You'd need 175+ million merchant locations to install your acceptance mark. You'd need fraud models trained on hundreds of billions of historical transactions. You'd need dispute resolution rules that consumers and merchants trust. You'd need regulatory approval in every jurisdiction. You'd need a brand that a shopkeeper in Lagos and a luxury retailer in Paris both recognize. And you'd need all of these things simultaneously, because a network with cardholders but no merchants is useless, and a network with merchants but no cardholders is equally dead. This is the three-sided network effect in its purest form. Consumers carry Visa because it's accepted everywhere. Merchants accept Visa because consumers carry it. Banks issue Visa because both sides already participate. Each new participant makes the network more valuable for everyone else, and the reinforcement has been compounding for 67 years. No amount of capital can shortcut the trust accumulation that comes from processing billions of transactions without systemic failure. The economic structure amplifies the defensibility. Because Visa doesn't bear credit risk, it doesn't need the massive capital buffers that banks maintain. It operates with minimal tangible assets — its value is in software, rules, relationships, and data. This produces return on equity above 40% and free cash flow that funds continuous reinvestment in security, speed, and new capabilities. A competitor trying to match Visa's fraud detection would need comparable training data — and Visa's AI models are trained on the largest transaction dataset in the world. The institutional switching costs are measured in years, not months. A bank that wants to move its card portfolio from Visa to a competitor faces technology migration, regulatory re-approval, customer communication, rewards program restructuring, and the risk of confusing millions of cardholders. Most banks simply don't bother. They issue both Visa and Mastercard and compete on rewards rather than network choice. Where the advantage shows cracks: pricing power in markets where governments can mandate cheaper alternatives. India proved that a well-designed national system can achieve massive scale without card networks. But even there, Visa remains relevant for cross-border transactions, premium cards, and the fraud/identity layer that domestic systems often lack.

Future prospects matter as much as current results. The growth strategies below explain how Novo Nordisk A/S and Visa Inc. each plan to expand from here.

Novo Nordisk A/S growth strategy: The introduction of Victoza (liraglutide) in 2009 marked the first shift toward incretin therapies, but it was the 2017 launch of Ozempic and the 2021 launch of Wegovy that triggered a paradigm shift in global medicine, transforming obesity from a lifestyle condition treated with behavioral counseling into a chronic neurological disease requiring lifelong pharmacological intervention. The remaining 26% of revenue is generated by legacy insulin analogs (Insulin glargine, Insulin aspart), growth hormone therapies, and hemophilia treatments, a portfolio that is growing at a low single-digit rate and serves primarily as a stable cash-flow baseline. To mitigate the risks associated with this extreme concentration, the business model incorporates aggressive inorganic growth and massive organic capital expenditure. The company uses its substantial free cash flow to acquire clinical-stage biotechnology companies and secure manufacturing capacity. This vertical integration strategy is designed to control the entire value chain, from the bacterial fermentation of the semaglutide peptide in Kalundborg, Denmark, to the final assembly of the FlexTouch injection pens in Hillerød, Denmark, and Clayton, North Carolina. This dynamic forces the company to maintain exceptionally high list prices to preserve its net revenue margins, a strategy that attracts intense political and regulatory scrutiny in the US and Europe. The ultimate goal of the business model is to achieve a sustainable compound annual growth rate (CAGR) of 15-20% at constant currency through 2030, a target that requires the successful launch of next-generation assets like CagriSema and oral amycretin, and the continuous expansion of manufacturing capacity to meet the estimated 1 billion obese patients globally who are candidates for pharmacological intervention. This logistical constraint creates a massive barrier to entry for competitors, as it requires the establishment of a decentralized network of specialized fill-finish facilities and cold-chain distribution partners, a capital-intensive infrastructure that Novo Nordisk has spent the last decade building through strategic acquisitions and organic investment. For Ozempic, the company has continuously expanded the label to include new indications such as cardiovascular risk reduction (based on the SELECT trial data) and chronic kidney disease, while also launching higher-dose formulations to improve glycemic control. The company's research centers in Bagsværd, Måløv, Oxford, and Cambridge focus on advanced areas such as oral peptide delivery, multi-receptor agonism, and gene editing. Novo Nordisk's response has been to pivot its diabetes portfolio toward combination therapies, such as the fixed-ratio combination of Insulin degludec and liraglutide (Xultophy), and to position its GLP-1 assets as the primary growth engine for the future. Novo Nordisk's competitive strategy in this space relies on continuous lifecycle management, launching new formulations and delivery methods to extend patent life and maintain premium pricing. To counter this, Novo Nordisk has adopted a 'buy and partner' strategy, using its massive balance sheet to acquire clinical-stage biotechs and secure exclusive rights to early-stage assets like Zealand Pharma's amycretin, effectively outsourcing the early-stage discovery risk to the private markets and then using its global commercial infrastructure to maximize the value of the assets. Novo Nordisk has responded by aggressively expanding its cardiovascular outcomes trial program, conducting the FLOW trial to evaluate the impact of semaglutide on chronic kidney disease, and the SELECT trial to evaluate its impact on major adverse cardiovascular events in non-diabetic obese patients. Selling, general, and administrative expenses were tightly controlled, growing at a slower rate than revenue, which contributed to the margin expansion. This capital return strategy is designed to support the stock price during the transition period between legacy insulin patents and new GLP-1 launches, signaling management's confidence in the long-term cash generation capabilities of the incretin-focused model. The FY2024 financial performance validates the strategic decision to pivot aggressively toward obesity therapeutics, as the removal of the low-margin legacy insulin focus has significantly improved the company's overall profitability metrics and return on invested capital. This substantial R&D investment is critical for maintaining the company's competitive position and driving future growth, and it is allocated across a diverse portfolio of early-stage discovery programs, Phase I and II clinical trials, and large-scale Phase III registrational studies like the SELECT and FLOW trials. Selling, general, and administrative (SG&A) expenses were 73.5 billion DKK, or 25.3% of net sales, reflecting the significant commercial investment required to launch and support the company's growing portfolio of GLP-1 therapies and navigate the complex PBM rebate landscape. The balance sheet at the end of FY2024 showed total assets of 412.5 billion DKK, total liabilities of 245.3 billion DKK, and total equity of 167.2 billion DKK, resulting in a debt-to-equity ratio of 0.65, which is well within the company's target range and provides a strong foundation for future growth and capital allocation initiatives. The implementation of the Inflation Reduction Act has enabled Medicare to negotiate drug prices, and while GLP-1s are currently excluded from the initial negotiation rounds due to their recent approval dates, the political momentum to include obesity therapies in future negotiations is growing rapidly. The commercial coverage of Wegovy for obesity is highly fragmented, with only a small percentage of commercial insurance plans and almost no Medicare plans covering the drug for weight loss alone, forcing Novo Nordisk to rely heavily on out-of-pocket payments and manufacturer copay cards, a strategy that is financially unsustainable in the long term. Finally, the company must manage the operational complexity of a massively expanded manufacturing footprint. Additionally, the company faces significant headwinds in the Chinese market, which has historically been a key driver of volume growth for its insulin portfolio. Novo Nordisk has responded by restructuring its commercial organization in China, shifting its focus toward a smaller portfolio of high-value innovative medicines like Ozempic, but the long-term impact of these regulatory pricing pressures on the company's growth trajectory in Asia remains a significant area of uncertainty for investors. The company's extensive experience in navigating the complex regulatory landscape for biologics, which involves coordination between multiple government agencies including the FDA, the EMA, and the WHO, provides it with a deep institutional knowledge base that accelerates the development and commercialization of new peptide assets. Novo Nordisk has invested billions of dollars in developing the FlexTouch and FlexTouch Plus injection devices, which are engineered to minimize injection site pain and ensure accurate dose delivery, a critical factor for patient compliance in chronic obesity treatment. Novo Nordisk A/S's growth strategy is built on three specific, named initiatives with clear financial targets: the acceleration of next-generation incretin therapy launches, the aggressive expansion of global manufacturing capacity through strategic acquisitions and organic investment, and the lifecycle management of key diabetes franchises. The company has committed to launching at least five new molecular entities or major label expansions between 2024 and 2030, a pipeline that includes potential blockbusters in obesity, diabetes, cardiovascular disease, and rare diseases. The incretin initiative is the cornerstone of this strategy, with the company investing heavily in clinical trials and manufacturing capacity to launch CagriSema, oral amycretin, and next-generation multi-receptor agonists. The manufacturing growth strategy focuses on eliminating the physical supply constraints that have limited Wegovy sales by executing a 28.6 billion DKK capital expenditure program to expand API and FDF capacity. The diabetes lifecycle management strategy aims to extend the commercial life of Insulin degludec and Insulin icodec by launching new combination therapies, such as fixed-ratio combinations with GLP-1 receptor agonists, and expanding into new indications like cardiovascular risk reduction. By continuously expanding the clinical utility of these assets, Novo Nordisk can defend against biosimilar competition and maintain premium pricing in key markets. To fund these initiatives, the company maintains a disciplined capital allocation framework that prioritizes R&D investment and targeted manufacturing acquisitions over large-scale, transformational mergers. The acquisition of Catalent and the partnership with Zealand Pharma exemplify this approach, providing the company with de-risked, late-stage assets and critical manufacturing capacity that can be integrated into the existing commercial infrastructure to drive immediate revenue growth. The execution of this growth strategy requires a highly skilled and motivated workforce, and Novo Nordisk has invested heavily in talent acquisition and development to ensure that it has the necessary scientific and commercial expertise to succeed. Novo Nordisk has also implemented a comprehensive training and development program for its employees, focusing on building the skills and capabilities required to succeed in the rapidly evolving pharmaceutical industry. The company's culture of innovation and collaboration is a key enabler of its growth strategy, fostering an environment where employees are encouraged to think creatively, take calculated risks, and work together to solve complex scientific and commercial challenges. The growth strategy also includes a strong focus on sustainability and corporate social responsibility, recognizing that the long-term success of the company is inextricably linked to the health and well-being of the communities in which it operates. Novo Nordisk has committed to achieving net zero greenhouse gas emissions across its value chain by 2030, and has implemented a comprehensive environmental, social, and governance (ESG) program that focuses on reducing its environmental footprint, promoting diversity and inclusion, and ensuring access to healthcare for underserved populations. The company's ESG initiatives are integrated into its overall business strategy, and its performance against these goals is regularly monitored and reported to stakeholders. The successful execution of Novo Nordisk's growth strategy will require the company to navigate a complex and dynamic external environment, characterized by rapid technological change, intense competition, and evolving regulatory and pricing pressures. However, the company's strong scientific heritage, strong pipeline, and disciplined capital allocation strategy provide a solid foundation for future growth, and its commitment to innovation and patient-centricity positions it well to deliver on its strategic objectives and create significant value for all stakeholders. The company projects a 15-20% constant currency sales CAGR from 2024 to 2030, a growth rate that relies heavily on the successful commercial launch of next-generation pipeline assets currently in Phase III trials. In the diabetes space, the launch of Insulin icodec (Awiqli), a once-weekly basal insulin, is expected to drive significant revenue growth and displace legacy daily insulin analogs, a therapeutic area where Novo Nordisk now holds a near-monopoly position in the weekly dosing category. Novo Nordisk has partnered with leading AI companies to identify novel peptide sequences and predict patient responses to therapy, a strategy that could significantly reduce the time and cost required to bring new drugs to market. In addition to GLP-1s, Novo Nordisk is heavily invested in the development of gene therapies and RNA-based therapeutics for rare bleeding disorders and rare endocrine diseases. The company's pipeline includes several gene therapy programs for hemophilia A and B, as well as a strong portfolio of siRNA therapeutics developed through its internal research and external partnerships. Novo Nordisk has invested heavily in its gene therapy manufacturing facilities in Denmark and the US, and has established a dedicated commercial team to support the launch of these complex therapies. The company is also exploring the use of digital biomarkers and wearable devices to collect real-time patient data during clinical trials, which could provide more sensitive and objective measures of drug efficacy and accelerate the regulatory approval process. The successful implementation of these digital health initiatives has the potential to significantly improve the productivity of the company's R&D organization and reduce the attrition rate of clinical candidates, ultimately leading to the faster and more efficient development of new medicines. The company faces intense competition in all of its key therapeutic areas, and the failure of any of its late-stage pipeline assets could have a material adverse impact on its financial performance and growth trajectory. Despite these challenges, Novo Nordisk's strong portfolio of innovative medicines, strong pipeline, and disciplined capital allocation strategy position it well to deliver sustained long-term growth and create significant value for its shareholders. Nordisk focused on purification and prolonged-action insulins, while Novo pioneered the use of recombinant DNA technology to produce human insulin. The early years of Novo Nordisk were marked by constant restructuring and a series of high-profile acquisitions designed to fill pipeline gaps, including the purchase of Genentech's insulin production rights and the expansion into hemophilia and growth hormone therapies.

Visa Inc. growth strategy: Visa's growth thesis under Ryan McInerney boils down to one bet: the company can evolve from the dominant card network into the default trust layer for all digital money movement. Everything else is execution detail. The two moves that actually matter are value-added services and new payment flows. Value-added services — fraud tools, tokenization, consulting, analytics, identity, dispute management — generated $10.9 billion in FY2025. That's not a side business anymore. It's a quarter of revenue, growing faster than core processing, and it's strategically critical because it gives Visa a reason to exist even when the payment doesn't travel on card rails. If a bank uses Visa's AI fraud scoring on an account-to-account transfer, Visa earns without a card being involved. Visa Direct is the other structural play. It enables real-time push payments — gig worker payouts, insurance disbursements, marketplace seller payments, cross-border remittances — that bypass traditional card-present transactions entirely. The volume is growing rapidly because businesses want to pay people instantly, and Visa's existing network of bank endpoints makes it faster to deploy than building new connections from scratch. The rest — tap-to-pay acceleration, credential expansion into wearables and IoT, open banking through Tink, issuer processing through Pismo — are all variations on the same theme: make Visa useful in more contexts, for more transaction types, through more form factors. The tap-to-pay push in the U.S. (now above 40% of face-to-face transactions, up from single digits five years ago) matters because it converts small cash purchases into network transactions. Every $3 coffee paid by tap instead of cash is incremental volume. The geographic opportunity is straightforward: cash still dominates daily commerce in much of Africa, Southeast Asia, and Latin America. As those economies digitize — through phones, not plastic — Visa wants its credentials and infrastructure embedded in whatever payment form emerges.

A closer look at the financial trajectory of Novo Nordisk A/S and Visa Inc. rounds out the comparison.

Novo Nordisk A/S: Revenue grew from $24.8 billion in FY2022 to $33.4 billion in FY2023 to $42.7 billion in FY2024 — a two-year compound growth rate of approximately 31% that is, for a company of this size, essentially without precedent in pharmaceutical history. Operating profit reached 125.3 billion DKK in FY2024, with an operating margin of 43.1%. Free cash flow of 91.2 billion DKK was deployed partially into the record 28.6 billion DKK capital expenditure program to expand manufacturing capacity. The semaglutide franchise breakdown illustrates the market's composition: Ozempic (diabetes indication) generated 146.9 billion DKK, Wegovy (obesity indication) generated 68.2 billion DKK. The obesity market is structurally larger than the diabetes market in terms of addressable population, and Wegovy's growth rate in FY2024 significantly exceeded Ozempic's — suggesting that the revenue mix will continue shifting toward obesity over the medium term as manufacturing constraints ease and insurance coverage expands. The capital expenditure program of 28.6 billion DKK in FY2024 — the largest in European pharmaceutical history — reflects the magnitude of the capacity constraint. Novo Nordisk's active pharmaceutical ingredient production and sterile fill-finish capabilities cannot scale quickly; the regulatory requirements for pharmaceutical manufacturing mean that new capacity requires years of construction and validation before it can produce commercial product. Novo Holdings' acquisition of Catalent was intended to accelerate that timeline by acquiring existing validated facilities rather than building from scratch. The $550 billion market capitalization at fiscal year-end made Novo Nordisk the most valuable company in Europe by a significant margin, representing approximately 12.9x FY2024 revenue. That multiple prices in continued semaglutide dominance, successful next-generation product launches, and the expansion of GLP-1 indications beyond diabetes and obesity into cardiovascular disease, chronic kidney disease, and potentially other metabolic conditions.

Visa Inc.: Visa earned $20.1 billion in net income on $40 billion in revenue in fiscal 2025 — a 50 percent net margin on a payments network that requires no lending capital and carries no credit losses. That number is the clearest single expression of what monopoly-adjacent infrastructure economics look like. Revenue has compounded at a steady pace: $29.3 billion in fiscal 2022, $32.7 billion in 2023, $40B in FY2025, $40 billion in 2025. The growth comes primarily from payment volume, cross-border transactions (which carry higher fees than domestic ones), and the continued displacement of cash by card and digital payments in markets outside North America. The market capitalization of $759 billion as of the most recent data reflects investors pricing in decades of durable cash generation. With 31,000 employees, that translates to roughly $24 million in market cap per employee — a ratio that reflects the asset-light, fee-based structure. The 2024 Pismo acquisition and the earlier Featurespace deal signal where incremental investment is going: cloud-native banking infrastructure and fraud detection AI. Neither represents a massive capital outlay relative to Visa's cash flows, but both extend the surface area of what Visa can charge for beyond pure transaction routing.